PortalPublikationenDevelopment and characterization of an indirect ELISA to det...

Development and characterization of an indirect ELISA to detect SARS-CoV - 2 spike protein-specific antibodies

Standard

Development and characterization of an indirect ELISA to detect SARS-CoV - 2 spike protein-specific antibodies. / Krähling, Verena; Halwe, Sandro; Rohde, Cornelius; Becker, Dirk; Berghöfer, Susanne; Dahlke, Christine; Eickmann, Markus; Ercanoglu, Meryem S; Gieselmann, Lutz; Herwig, Astrid; Kupke, Alexandra; Müller, Helena; Neubauer-Rädel, Petra; Klein, Florian; Keller, Christian; Becker, Stephan.

in: J IMMUNOL METHODS, Jahrgang 490, 112958, 03.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Krähling, V, Halwe, S, Rohde, C, Becker, D, Berghöfer, S, Dahlke, C, Eickmann, M, Ercanoglu, MS, Gieselmann, L, Herwig, A, Kupke, A, Müller, H, Neubauer-Rädel, P, Klein, F, Keller, C & Becker, S 2021, 'Development and characterization of an indirect ELISA to detect SARS-CoV - 2 spike protein-specific antibodies', J IMMUNOL METHODS, Jg. 490, 112958. https://doi.org/10.1016/j.jim.2021.112958

APA

Krähling, V., Halwe, S., Rohde, C., Becker, D., Berghöfer, S., Dahlke, C., Eickmann, M., Ercanoglu, M. S., Gieselmann, L., Herwig, A., Kupke, A., Müller, H., Neubauer-Rädel, P., Klein, F., Keller, C., & Becker, S. (2021). Development and characterization of an indirect ELISA to detect SARS-CoV - 2 spike protein-specific antibodies. J IMMUNOL METHODS, 490, [112958]. https://doi.org/10.1016/j.jim.2021.112958

Vancouver

Krähling V, Halwe S, Rohde C, Becker D, Berghöfer S, Dahlke C et al. Development and characterization of an indirect ELISA to detect SARS-CoV - 2 spike protein-specific antibodies. J IMMUNOL METHODS. 2021 Mär;490. 112958. https://doi.org/10.1016/j.jim.2021.112958

Bibtex

@article{6903edbdc71c46e3bcde61ac0c2b00a3,
title = "Development and characterization of an indirect ELISA to detect SARS-CoV - 2 spike protein-specific antibodies",
abstract = "The current Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic is a public health emergency of international concern. Sensitive and precise diagnostic tools are urgently needed. In this study, we developed a SARS-CoV-2 spike (S1) protein enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2-specific antibodies. The SARS-CoV-2 S1 ELISA was found to be specific [97.8% (95% CI, 96.7% - 98.5%)], reproducible and precise (intra-assay coefficient of variability (CV) 5.3%, inter-assay CV 7.9%). A standard curve and the interpolation of arbitrary ELISA units per milliliter served to reduce the variability between different tests and operators. Cross-reactivity to other human coronaviruses was addressed by using sera positive for MERS-CoV- and hCoV HKU1-specific antibodies. Monitoring antibody development in various samples of twenty-three and single samples of twenty-nine coronavirus disease 2019 (COVID-19) patients revealed seroconversion and neutralizing antibodies against authentic SARS-CoV-2 in all cases. The comparison of the SARS-CoV-2 (S1) ELISA with a commercially available assay showed a better sensitivity for the in-house ELISA. The results demonstrate a high reproducibility, specificity and sensitivity of the newly developed ELISA, which is suitable for the detection of SARS-CoV-2 S1 protein-specific antibody responses.",
author = "Verena Kr{\"a}hling and Sandro Halwe and Cornelius Rohde and Dirk Becker and Susanne Bergh{\"o}fer and Christine Dahlke and Markus Eickmann and Ercanoglu, {Meryem S} and Lutz Gieselmann and Astrid Herwig and Alexandra Kupke and Helena M{\"u}ller and Petra Neubauer-R{\"a}del and Florian Klein and Christian Keller and Stephan Becker",
note = "Copyright {\textcopyright} 2019. Published by Elsevier B.V.",
year = "2021",
month = mar,
doi = "10.1016/j.jim.2021.112958",
language = "English",
volume = "490",
journal = "J IMMUNOL METHODS",
issn = "0022-1759",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Development and characterization of an indirect ELISA to detect SARS-CoV - 2 spike protein-specific antibodies

AU - Krähling, Verena

AU - Halwe, Sandro

AU - Rohde, Cornelius

AU - Becker, Dirk

AU - Berghöfer, Susanne

AU - Dahlke, Christine

AU - Eickmann, Markus

AU - Ercanoglu, Meryem S

AU - Gieselmann, Lutz

AU - Herwig, Astrid

AU - Kupke, Alexandra

AU - Müller, Helena

AU - Neubauer-Rädel, Petra

AU - Klein, Florian

AU - Keller, Christian

AU - Becker, Stephan

N1 - Copyright © 2019. Published by Elsevier B.V.

PY - 2021/3

Y1 - 2021/3

N2 - The current Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic is a public health emergency of international concern. Sensitive and precise diagnostic tools are urgently needed. In this study, we developed a SARS-CoV-2 spike (S1) protein enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2-specific antibodies. The SARS-CoV-2 S1 ELISA was found to be specific [97.8% (95% CI, 96.7% - 98.5%)], reproducible and precise (intra-assay coefficient of variability (CV) 5.3%, inter-assay CV 7.9%). A standard curve and the interpolation of arbitrary ELISA units per milliliter served to reduce the variability between different tests and operators. Cross-reactivity to other human coronaviruses was addressed by using sera positive for MERS-CoV- and hCoV HKU1-specific antibodies. Monitoring antibody development in various samples of twenty-three and single samples of twenty-nine coronavirus disease 2019 (COVID-19) patients revealed seroconversion and neutralizing antibodies against authentic SARS-CoV-2 in all cases. The comparison of the SARS-CoV-2 (S1) ELISA with a commercially available assay showed a better sensitivity for the in-house ELISA. The results demonstrate a high reproducibility, specificity and sensitivity of the newly developed ELISA, which is suitable for the detection of SARS-CoV-2 S1 protein-specific antibody responses.

AB - The current Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic is a public health emergency of international concern. Sensitive and precise diagnostic tools are urgently needed. In this study, we developed a SARS-CoV-2 spike (S1) protein enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2-specific antibodies. The SARS-CoV-2 S1 ELISA was found to be specific [97.8% (95% CI, 96.7% - 98.5%)], reproducible and precise (intra-assay coefficient of variability (CV) 5.3%, inter-assay CV 7.9%). A standard curve and the interpolation of arbitrary ELISA units per milliliter served to reduce the variability between different tests and operators. Cross-reactivity to other human coronaviruses was addressed by using sera positive for MERS-CoV- and hCoV HKU1-specific antibodies. Monitoring antibody development in various samples of twenty-three and single samples of twenty-nine coronavirus disease 2019 (COVID-19) patients revealed seroconversion and neutralizing antibodies against authentic SARS-CoV-2 in all cases. The comparison of the SARS-CoV-2 (S1) ELISA with a commercially available assay showed a better sensitivity for the in-house ELISA. The results demonstrate a high reproducibility, specificity and sensitivity of the newly developed ELISA, which is suitable for the detection of SARS-CoV-2 S1 protein-specific antibody responses.

U2 - 10.1016/j.jim.2021.112958

DO - 10.1016/j.jim.2021.112958

M3 - SCORING: Journal article

C2 - 33412174

VL - 490

JO - J IMMUNOL METHODS

JF - J IMMUNOL METHODS

SN - 0022-1759

M1 - 112958

ER -